Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.53 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.53 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.51 |
| ▸ | STAT3 | P40763 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120573 | 0.89 | EGFR (0.53) | CRBNBRD9BRD7EGFRERBB2 | |
| SCHEMBL20120558 | 0.89 | EGFR (0.53) | CRBNBRD9BRD7EGFRERBB2 | |
| SCHEMBL20120282 | 0.89 | EGFR (0.53) | CRBNBRD9BRD7EGFRERBB2 | |
| SCHEMBL29548103 | 0.89 | EGFR (0.53) | CRBNBRD9BRD7EGFRERBB2 | |
| SCHEMBL29547458 | 0.85 | BRD9 (0.49) | BRD9 | |
| SCHEMBL20120846 | 0.85 | BRD9 (0.49) | BRD9 | |
| SCHEMBL20120317 | 0.85 | BRD9 (0.49) | BRD9 | |
| SCHEMBL23418132 | 0.83 | CRBN (0.56) | CRBNBRD9BRD7EGFRERBB2 | |
| SCHEMBL20128982 | 0.82 | CRBN (0.53) | CRBNBRD9BRD7EGFRERBB2 | |
| SCHEMBL20120827 | 0.82 | EGFR (0.60) | CRBNBRD9BRD7EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3535265-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | CRBN 1/4885BRD9 1141/4885BRD7 1111/4885 |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | CRBN, VHL, UBQLN2 | CRBN 1/4885BRD9 1141/4885BRD7 1111/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | CRBN 1/4885BRD9 1141/4885BRD7 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.